Add this topic to your myFT Digest for news straight to your inbox
US biotech company’s stock worth nearly $500 at its peak in August 2021, currently trades at less than $87
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Pharma group behind blockbuster drug wants to supersize its market impact
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Decision is setback for US drugmaker looking to increase sales after pandemic
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
Drugmaker upbeat on full data after initial findings disappointed investors
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
No, but it’s mildly interesting to ask
Drugmaker praises country’s scientific expertise but says it must address conflicts in areas such as drug pricing
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
Using AI should speed up detection of diseases caused by genetic variants but it does not guarantee success
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Unlike the vaccine race, there is limited funding to treat a condition that is often debilitating
Medicare’s negotiations on the cost of medicines could affect how drug research is funded globally
New model aims to reduce high development costs and increase number of drugs being tested
Antimicrobial resistance already kills millions and is projected to get worse. But there is little incentive for Big Pharma to tackle the issue
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
International Edition